nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipivefrin—ACHE—breast cancer	0.459	0.63	CbGaD
Dipivefrin—BCHE—breast cancer	0.27	0.37	CbGaD
Dipivefrin—ACHE—Irinotecan—breast cancer	0.0709	0.624	CbGbCtD
Dipivefrin—BCHE—Irinotecan—breast cancer	0.0427	0.376	CbGbCtD
Dipivefrin—Bambuterol—BCHE—breast cancer	0.00265	0.77	CrCbGaD
Dipivefrin—Arrhythmia—Toremifene—breast cancer	0.00117	0.0255	CcSEcCtD
Dipivefrin—Stinging—Fluorouracil—breast cancer	0.00116	0.0253	CcSEcCtD
Dipivefrin—Hypersensitivity—Fluoxymesterone—breast cancer	0.00106	0.0231	CcSEcCtD
Dipivefrin—Conjunctivitis—Raloxifene—breast cancer	0.00105	0.0229	CcSEcCtD
Dipivefrin—Pain—Carboplatin—breast cancer	0.000929	0.0202	CcSEcCtD
Dipivefrin—Arrhythmia—Idarubicin—breast cancer	0.000867	0.0189	CcSEcCtD
Dipivefrin—Hypertension—Exemestane—breast cancer	0.000865	0.0188	CcSEcCtD
Dipivefrin—Pain—Fulvestrant—breast cancer	0.000805	0.0175	CcSEcCtD
Dipivefrin—Pain—Toremifene—breast cancer	0.000795	0.0173	CcSEcCtD
Dipivefrin—Hypertension—Anastrozole—breast cancer	0.000769	0.0167	CcSEcCtD
Dipivefrin—Hypertension—Letrozole—breast cancer	0.000769	0.0167	CcSEcCtD
Dipivefrin—Hypersensitivity—Lapatinib—breast cancer	0.000754	0.0164	CcSEcCtD
Dipivefrin—Tachycardia—Letrozole—breast cancer	0.000709	0.0155	CcSEcCtD
Dipivefrin—Pain—Exemestane—breast cancer	0.000699	0.0152	CcSEcCtD
Dipivefrin—Hypersensitivity—Fulvestrant—breast cancer	0.000694	0.0151	CcSEcCtD
Dipivefrin—Pain—Ixabepilone—breast cancer	0.00066	0.0144	CcSEcCtD
Dipivefrin—Arrhythmia—Tamoxifen—breast cancer	0.000625	0.0136	CcSEcCtD
Dipivefrin—Pain—Letrozole—breast cancer	0.000621	0.0135	CcSEcCtD
Dipivefrin—Pain—Anastrozole—breast cancer	0.000621	0.0135	CcSEcCtD
Dipivefrin—Conjunctivitis—Thiotepa—breast cancer	0.000619	0.0135	CcSEcCtD
Dipivefrin—Arrhythmia—Melphalan—breast cancer	0.000612	0.0133	CcSEcCtD
Dipivefrin—Hypersensitivity—Exemestane—breast cancer	0.000602	0.0131	CcSEcCtD
Dipivefrin—Arrhythmia—Goserelin—breast cancer	0.000597	0.013	CcSEcCtD
Dipivefrin—Pain—Raloxifene—breast cancer	0.00059	0.0128	CcSEcCtD
Dipivefrin—Hypersensitivity—Ixabepilone—breast cancer	0.000568	0.0124	CcSEcCtD
Dipivefrin—Stinging—Epirubicin—breast cancer	0.000566	0.0123	CcSEcCtD
Dipivefrin—Hypertension—Vinblastine—breast cancer	0.000541	0.0118	CcSEcCtD
Dipivefrin—Hypersensitivity—Anastrozole—breast cancer	0.000535	0.0117	CcSEcCtD
Dipivefrin—Arrhythmia—Vinorelbine—breast cancer	0.000535	0.0117	CcSEcCtD
Dipivefrin—Conjunctivitis—Mitoxantrone—breast cancer	0.000535	0.0116	CcSEcCtD
Dipivefrin—Epinephrine—TNF—breast cancer	0.000533	0.155	CrCbGaD
Dipivefrin—Hypertension—Tamoxifen—breast cancer	0.000526	0.0115	CcSEcCtD
Dipivefrin—Stinging—Doxorubicin—breast cancer	0.000524	0.0114	CcSEcCtD
Dipivefrin—Conjunctivitis—Fluorouracil—breast cancer	0.000512	0.0112	CcSEcCtD
Dipivefrin—Arrhythmia—Thiotepa—breast cancer	0.000511	0.0111	CcSEcCtD
Dipivefrin—Hypersensitivity—Idarubicin—breast cancer	0.000508	0.0111	CcSEcCtD
Dipivefrin—Hypertension—Goserelin—breast cancer	0.000502	0.0109	CcSEcCtD
Dipivefrin—Pain—Chlorambucil—breast cancer	0.000478	0.0104	CcSEcCtD
Dipivefrin—Tachycardia—Melphalan—breast cancer	0.000475	0.0104	CcSEcCtD
Dipivefrin—Tachycardia—Goserelin—breast cancer	0.000463	0.0101	CcSEcCtD
Dipivefrin—Hypertension—Vinorelbine—breast cancer	0.00045	0.0098	CcSEcCtD
Dipivefrin—Arrhythmia—Irinotecan—breast cancer	0.000441	0.00961	CcSEcCtD
Dipivefrin—Arrhythmia—Mitoxantrone—breast cancer	0.000441	0.00961	CcSEcCtD
Dipivefrin—Pain—Vinblastine—breast cancer	0.000438	0.00954	CcSEcCtD
Dipivefrin—Conjunctivitis—Paclitaxel—breast cancer	0.000436	0.0095	CcSEcCtD
Dipivefrin—Hypertension—Thiotepa—breast cancer	0.00043	0.00936	CcSEcCtD
Dipivefrin—Arrhythmia—Gemcitabine—breast cancer	0.00043	0.00936	CcSEcCtD
Dipivefrin—Pain—Tamoxifen—breast cancer	0.000425	0.00926	CcSEcCtD
Dipivefrin—Arrhythmia—Fluorouracil—breast cancer	0.000422	0.00921	CcSEcCtD
Dipivefrin—Pain—Melphalan—breast cancer	0.000416	0.00907	CcSEcCtD
Dipivefrin—Tachycardia—Vinorelbine—breast cancer	0.000415	0.00905	CcSEcCtD
Dipivefrin—Hypersensitivity—Chlorambucil—breast cancer	0.000411	0.00897	CcSEcCtD
Dipivefrin—Pain—Goserelin—breast cancer	0.000406	0.00885	CcSEcCtD
Dipivefrin—Tachycardia—Thiotepa—breast cancer	0.000396	0.00864	CcSEcCtD
Dipivefrin—ADRA2C—nipple—breast cancer	0.000394	0.055	CbGeAlD
Dipivefrin—Hypersensitivity—Vinblastine—breast cancer	0.000377	0.00822	CcSEcCtD
Dipivefrin—Hypertension—Mitoxantrone—breast cancer	0.000371	0.00809	CcSEcCtD
Dipivefrin—Hypertension—Irinotecan—breast cancer	0.000371	0.00809	CcSEcCtD
Dipivefrin—Conjunctivitis—Docetaxel—breast cancer	0.00037	0.00805	CcSEcCtD
Dipivefrin—BCHE—nipple—breast cancer	0.000367	0.0513	CbGeAlD
Dipivefrin—Hypersensitivity—Tamoxifen—breast cancer	0.000366	0.00798	CcSEcCtD
Dipivefrin—ACHE—adrenal gland—breast cancer	0.000365	0.051	CbGeAlD
Dipivefrin—Pain—Vinorelbine—breast cancer	0.000364	0.00793	CcSEcCtD
Dipivefrin—Hypertension—Gemcitabine—breast cancer	0.000361	0.00788	CcSEcCtD
Dipivefrin—Arrhythmia—Paclitaxel—breast cancer	0.00036	0.00784	CcSEcCtD
Dipivefrin—Hypersensitivity—Melphalan—breast cancer	0.000359	0.00782	CcSEcCtD
Dipivefrin—Conjunctivitis—Capecitabine—breast cancer	0.000358	0.0078	CcSEcCtD
Dipivefrin—Hypersensitivity—Goserelin—breast cancer	0.00035	0.00762	CcSEcCtD
Dipivefrin—Pain—Thiotepa—breast cancer	0.000347	0.00757	CcSEcCtD
Dipivefrin—Tachycardia—Mitoxantrone—breast cancer	0.000342	0.00746	CcSEcCtD
Dipivefrin—Tachycardia—Fluorouracil—breast cancer	0.000328	0.00714	CcSEcCtD
Dipivefrin—ADRA2A—nipple—breast cancer	0.000314	0.0439	CbGeAlD
Dipivefrin—Hypersensitivity—Vinorelbine—breast cancer	0.000313	0.00683	CcSEcCtD
Dipivefrin—Arrhythmia—Docetaxel—breast cancer	0.000305	0.00664	CcSEcCtD
Dipivefrin—Hypertension—Paclitaxel—breast cancer	0.000303	0.00659	CcSEcCtD
Dipivefrin—Pain—Irinotecan—breast cancer	0.0003	0.00654	CcSEcCtD
Dipivefrin—Pain—Mitoxantrone—breast cancer	0.0003	0.00654	CcSEcCtD
Dipivefrin—Hypersensitivity—Thiotepa—breast cancer	0.000299	0.00652	CcSEcCtD
Dipivefrin—Arrhythmia—Capecitabine—breast cancer	0.000295	0.00643	CcSEcCtD
Dipivefrin—Pain—Gemcitabine—breast cancer	0.000292	0.00637	CcSEcCtD
Dipivefrin—Pain—Fluorouracil—breast cancer	0.000287	0.00626	CcSEcCtD
Dipivefrin—Tachycardia—Paclitaxel—breast cancer	0.000279	0.00608	CcSEcCtD
Dipivefrin—ADRA1A—epithelium—breast cancer	0.000278	0.0389	CbGeAlD
Dipivefrin—Conjunctivitis—Methotrexate—breast cancer	0.000266	0.0058	CcSEcCtD
Dipivefrin—Hypersensitivity—Irinotecan—breast cancer	0.000258	0.00563	CcSEcCtD
Dipivefrin—Hypersensitivity—Mitoxantrone—breast cancer	0.000258	0.00563	CcSEcCtD
Dipivefrin—Epinephrine—CYP3A4—breast cancer	0.000258	0.0752	CrCbGaD
Dipivefrin—Hypertension—Docetaxel—breast cancer	0.000257	0.00559	CcSEcCtD
Dipivefrin—Conjunctivitis—Epirubicin—breast cancer	0.000249	0.00543	CcSEcCtD
Dipivefrin—Hypertension—Capecitabine—breast cancer	0.000248	0.00541	CcSEcCtD
Dipivefrin—Hypersensitivity—Fluorouracil—breast cancer	0.000248	0.00539	CcSEcCtD
Dipivefrin—Pain—Paclitaxel—breast cancer	0.000245	0.00533	CcSEcCtD
Dipivefrin—ADRA2C—endometrium—breast cancer	0.000238	0.0332	CbGeAlD
Dipivefrin—Tachycardia—Docetaxel—breast cancer	0.000237	0.00516	CcSEcCtD
Dipivefrin—BCHE—skin of body—breast cancer	0.000235	0.0329	CbGeAlD
Dipivefrin—Conjunctivitis—Doxorubicin—breast cancer	0.000231	0.00503	CcSEcCtD
Dipivefrin—Tachycardia—Capecitabine—breast cancer	0.000229	0.00499	CcSEcCtD
Dipivefrin—ADRA1A—adipose tissue—breast cancer	0.000225	0.0314	CbGeAlD
Dipivefrin—BCHE—endometrium—breast cancer	0.000222	0.031	CbGeAlD
Dipivefrin—ADRA2C—uterus—breast cancer	0.000219	0.0306	CbGeAlD
Dipivefrin—ACHE—lymph node—breast cancer	0.000219	0.0305	CbGeAlD
Dipivefrin—ADRA2C—pituitary gland—breast cancer	0.000215	0.0301	CbGeAlD
Dipivefrin—ADRA2C—adipose tissue—breast cancer	0.000214	0.0299	CbGeAlD
Dipivefrin—Hypersensitivity—Paclitaxel—breast cancer	0.000211	0.00459	CcSEcCtD
Dipivefrin—Pain—Docetaxel—breast cancer	0.000207	0.00452	CcSEcCtD
Dipivefrin—Arrhythmia—Epirubicin—breast cancer	0.000206	0.00448	CcSEcCtD
Dipivefrin—BCHE—uterus—breast cancer	0.000204	0.0285	CbGeAlD
Dipivefrin—ADRA1A—adrenal gland—breast cancer	0.000202	0.0282	CbGeAlD
Dipivefrin—Pain—Capecitabine—breast cancer	0.000201	0.00437	CcSEcCtD
Dipivefrin—BCHE—pituitary gland—breast cancer	0.000201	0.028	CbGeAlD
Dipivefrin—BCHE—adipose tissue—breast cancer	0.0002	0.0279	CbGeAlD
Dipivefrin—ADRA2C—adrenal gland—breast cancer	0.000192	0.0268	CbGeAlD
Dipivefrin—Arrhythmia—Doxorubicin—breast cancer	0.00019	0.00415	CcSEcCtD
Dipivefrin—ADRA2A—endometrium—breast cancer	0.00019	0.0265	CbGeAlD
Dipivefrin—BCHE—female reproductive system—breast cancer	0.000184	0.0257	CbGeAlD
Dipivefrin—BCHE—adrenal gland—breast cancer	0.000179	0.025	CbGeAlD
Dipivefrin—ADRA2C—female gonad—breast cancer	0.000179	0.025	CbGeAlD
Dipivefrin—Hypersensitivity—Docetaxel—breast cancer	0.000179	0.00389	CcSEcCtD
Dipivefrin—ADRA1A—endocrine gland—breast cancer	0.000175	0.0244	CbGeAlD
Dipivefrin—ADRA2A—uterus—breast cancer	0.000175	0.0244	CbGeAlD
Dipivefrin—BCHE—bone marrow—breast cancer	0.000173	0.0242	CbGeAlD
Dipivefrin—Hypertension—Epirubicin—breast cancer	0.000173	0.00377	CcSEcCtD
Dipivefrin—Hypersensitivity—Capecitabine—breast cancer	0.000173	0.00377	CcSEcCtD
Dipivefrin—ADRA2A—pituitary gland—breast cancer	0.000172	0.024	CbGeAlD
Dipivefrin—ADRA2A—adipose tissue—breast cancer	0.000171	0.0239	CbGeAlD
Dipivefrin—Hypertension—Doxorubicin—breast cancer	0.00016	0.00349	CcSEcCtD
Dipivefrin—Tachycardia—Epirubicin—breast cancer	0.00016	0.00348	CcSEcCtD
Dipivefrin—ADRA2A—female reproductive system—breast cancer	0.000157	0.022	CbGeAlD
Dipivefrin—BCHE—endocrine gland—breast cancer	0.000155	0.0217	CbGeAlD
Dipivefrin—ADRA2A—adrenal gland—breast cancer	0.000153	0.0214	CbGeAlD
Dipivefrin—Pain—Methotrexate—breast cancer	0.000149	0.00326	CcSEcCtD
Dipivefrin—Tachycardia—Doxorubicin—breast cancer	0.000148	0.00322	CcSEcCtD
Dipivefrin—ADRA2A—female gonad—breast cancer	0.000143	0.02	CbGeAlD
Dipivefrin—Pain—Epirubicin—breast cancer	0.00014	0.00305	CcSEcCtD
Dipivefrin—ADRA2A—endocrine gland—breast cancer	0.000133	0.0186	CbGeAlD
Dipivefrin—Pain—Doxorubicin—breast cancer	0.000129	0.00282	CcSEcCtD
Dipivefrin—Hypersensitivity—Methotrexate—breast cancer	0.000129	0.00281	CcSEcCtD
Dipivefrin—Hypersensitivity—Epirubicin—breast cancer	0.000121	0.00263	CcSEcCtD
Dipivefrin—ADRA2C—lymph node—breast cancer	0.000115	0.0161	CbGeAlD
Dipivefrin—Hypersensitivity—Doxorubicin—breast cancer	0.000111	0.00243	CcSEcCtD
Dipivefrin—BCHE—lymph node—breast cancer	0.000107	0.015	CbGeAlD
Dipivefrin—ADRA2A—lymph node—breast cancer	9.19e-05	0.0128	CbGeAlD
Dipivefrin—ADRA2B—Signaling Pathways—SERPINE1—breast cancer	5.96e-06	5.9e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—PIK3CD—breast cancer	5.95e-06	5.89e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—ESR1—breast cancer	5.92e-06	5.87e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—HIF1A—breast cancer	5.91e-06	5.85e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—KRAS—breast cancer	5.9e-06	5.84e-05	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR downstream signaling—PIK3CA—breast cancer	5.89e-06	5.84e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—SERPINE1—breast cancer	5.89e-06	5.83e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—PIK3CB—breast cancer	5.87e-06	5.81e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—IGF1—breast cancer	5.86e-06	5.81e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—AKT2—breast cancer	5.86e-06	5.8e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Hemostasis—AKT1—breast cancer	5.86e-06	5.8e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—FN1—breast cancer	5.85e-06	5.79e-05	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—PTEN—breast cancer	5.84e-06	5.78e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—EGFR—breast cancer	5.84e-06	5.78e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—KRAS—breast cancer	5.83e-06	5.77e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—PTGS2—breast cancer	5.82e-06	5.76e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—NFKBIA—breast cancer	5.78e-06	5.72e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—LEP—breast cancer	5.76e-06	5.71e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—NOTCH1—breast cancer	5.73e-06	5.67e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CAV1—breast cancer	5.71e-06	5.66e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—NOS3—breast cancer	5.69e-06	5.64e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—KDR—breast cancer	5.65e-06	5.59e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—PIK3CD—breast cancer	5.63e-06	5.58e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—NOS3—breast cancer	5.62e-06	5.56e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—KIT—breast cancer	5.6e-06	5.54e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—APC—breast cancer	5.6e-06	5.54e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PIK3CG—breast cancer	5.6e-06	5.54e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR downstream signaling—PIK3CA—breast cancer	5.58e-06	5.52e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—SERPINE1—breast cancer	5.57e-06	5.51e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—EGF—breast cancer	5.53e-06	5.48e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—KRAS—breast cancer	5.51e-06	5.46e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—ESR1—breast cancer	5.5e-06	5.45e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PIK3CD—breast cancer	5.47e-06	5.42e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—FN1—breast cancer	5.44e-06	5.38e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—PIK3CA—breast cancer	5.42e-06	5.37e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—MDM2—breast cancer	5.4e-06	5.35e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—ALB—breast cancer	5.4e-06	5.35e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—RAF1—breast cancer	5.38e-06	5.33e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—NFKBIA—breast cancer	5.37e-06	5.32e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—MAPK3—breast cancer	5.36e-06	5.31e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—RELA—breast cancer	5.36e-06	5.31e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—PIK3CA—breast cancer	5.35e-06	5.3e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—MDM2—breast cancer	5.33e-06	5.28e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—ERBB2—breast cancer	5.32e-06	5.27e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—NOTCH1—breast cancer	5.32e-06	5.27e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—NOS3—breast cancer	5.32e-06	5.26e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—RAF1—breast cancer	5.31e-06	5.26e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—RELA—breast cancer	5.29e-06	5.24e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—BRAF—breast cancer	5.26e-06	5.21e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—ERBB2—breast cancer	5.26e-06	5.2e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—PIK3CB—breast cancer	5.25e-06	5.2e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—MTOR—breast cancer	5.25e-06	5.2e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—KIT—breast cancer	5.2e-06	5.15e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—APC—breast cancer	5.2e-06	5.15e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PIK3CG—breast cancer	5.2e-06	5.15e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—PIK3CB—breast cancer	5.19e-06	5.14e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—MTOR—breast cancer	5.19e-06	5.14e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—NOS3—breast cancer	5.16e-06	5.11e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—EGF—breast cancer	5.14e-06	5.09e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—IGF1—breast cancer	5.13e-06	5.08e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—AKT2—breast cancer	5.12e-06	5.07e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—EGFR—breast cancer	5.1e-06	5.05e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—PTEN—breast cancer	5.07e-06	5.02e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—PIK3CA—breast cancer	5.06e-06	5.02e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CXCL8—breast cancer	5.05e-06	5e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—MDM2—breast cancer	5.04e-06	4.99e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—RAF1—breast cancer	5.03e-06	4.98e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—HRAS—breast cancer	5.02e-06	4.97e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—RELA—breast cancer	5e-06	4.96e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CXCL8—breast cancer	4.98e-06	4.94e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—MAPK3—breast cancer	4.98e-06	4.93e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—ERBB2—breast cancer	4.97e-06	4.92e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—HRAS—breast cancer	4.95e-06	4.9e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CDKN1B—breast cancer	4.93e-06	4.88e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PIK3CD—breast cancer	4.92e-06	4.87e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—PIK3CB—breast cancer	4.91e-06	4.86e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—MTOR—breast cancer	4.91e-06	4.86e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—BRAF—breast cancer	4.89e-06	4.84e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR downstream signaling—AKT1—breast cancer	4.88e-06	4.83e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR downstream signaling—PIK3CA—breast cancer	4.88e-06	4.83e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—SERPINE1—breast cancer	4.87e-06	4.82e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CDKN1B—breast cancer	4.87e-06	4.82e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CASP3—breast cancer	4.83e-06	4.79e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—IL2—breast cancer	4.83e-06	4.78e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—KRAS—breast cancer	4.82e-06	4.77e-05	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR downstream signaling—AKT1—breast cancer	4.82e-06	4.77e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—IL6—breast cancer	4.8e-06	4.75e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CASP3—breast cancer	4.77e-06	4.72e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PIK3CB—breast cancer	4.77e-06	4.72e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—IL2—breast cancer	4.76e-06	4.72e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—IGF1—breast cancer	4.76e-06	4.72e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—AKT2—breast cancer	4.76e-06	4.71e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—IL6—breast cancer	4.74e-06	4.69e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—EGFR—breast cancer	4.74e-06	4.69e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PTGS2—breast cancer	4.72e-06	4.68e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CXCL8—breast cancer	4.72e-06	4.67e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CCND1—breast cancer	4.7e-06	4.66e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—JUN—breast cancer	4.69e-06	4.65e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—HRAS—breast cancer	4.69e-06	4.64e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CTNNB1—breast cancer	4.66e-06	4.61e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—NOS3—breast cancer	4.65e-06	4.6e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CCND1—breast cancer	4.64e-06	4.6e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—JUN—breast cancer	4.63e-06	4.59e-05	CbGpPWpGaD
Dipivefrin—ACHE—Metabolism—PIK3CA—breast cancer	4.62e-06	4.57e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CDKN1B—breast cancer	4.61e-06	4.56e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CTNNB1—breast cancer	4.6e-06	4.55e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PIK3CD—breast cancer	4.57e-06	4.53e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—MMP9—breast cancer	4.57e-06	4.52e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR downstream signaling—AKT1—breast cancer	4.56e-06	4.51e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CDKN1A—breast cancer	4.55e-06	4.51e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—PTEN—breast cancer	4.54e-06	4.5e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR downstream signaling—PIK3CA—breast cancer	4.53e-06	4.49e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—SERPINE1—breast cancer	4.52e-06	4.48e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CASP3—breast cancer	4.51e-06	4.47e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—MMP9—breast cancer	4.51e-06	4.46e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—IL2—breast cancer	4.51e-06	4.46e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CDKN1A—breast cancer	4.49e-06	4.45e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—IL6—breast cancer	4.48e-06	4.44e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—PTEN—breast cancer	4.48e-06	4.44e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—KRAS—breast cancer	4.48e-06	4.43e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—MAPK8—breast cancer	4.44e-06	4.4e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—AKT1—breast cancer	4.43e-06	4.39e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—PIK3CA—breast cancer	4.43e-06	4.38e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—MDM2—breast cancer	4.41e-06	4.37e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—RAF1—breast cancer	4.39e-06	4.35e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CCND1—breast cancer	4.39e-06	4.35e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—MAPK8—breast cancer	4.38e-06	4.34e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—JUN—breast cancer	4.38e-06	4.34e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—RELA—breast cancer	4.38e-06	4.33e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—AKT1—breast cancer	4.37e-06	4.33e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CTNNB1—breast cancer	4.35e-06	4.31e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—ERBB2—breast cancer	4.35e-06	4.31e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—NOS3—breast cancer	4.32e-06	4.28e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—MTOR—breast cancer	4.29e-06	4.25e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PIK3CB—breast cancer	4.29e-06	4.25e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—MMP9—breast cancer	4.27e-06	4.22e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CDKN1A—breast cancer	4.25e-06	4.21e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—PTEN—breast cancer	4.24e-06	4.2e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—SRC—breast cancer	4.21e-06	4.17e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—SRC—breast cancer	4.16e-06	4.12e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—MAPK8—breast cancer	4.15e-06	4.11e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—AKT1—breast cancer	4.14e-06	4.1e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CXCL8—breast cancer	4.12e-06	4.08e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PTEN—breast cancer	4.12e-06	4.08e-05	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—PIK3CA—breast cancer	4.12e-06	4.08e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—PIK3CA—breast cancer	4.11e-06	4.07e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—VEGFA—breast cancer	4.1e-06	4.06e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—MDM2—breast cancer	4.1e-06	4.06e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—HRAS—breast cancer	4.1e-06	4.06e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—RAF1—breast cancer	4.08e-06	4.04e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—RELA—breast cancer	4.07e-06	4.03e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—STAT3—breast cancer	4.06e-06	4.02e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—VEGFA—breast cancer	4.05e-06	4.01e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—ERBB2—breast cancer	4.04e-06	4e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CDKN1B—breast cancer	4.03e-06	3.99e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—STAT3—breast cancer	4.01e-06	3.97e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—MTOR—breast cancer	3.99e-06	3.95e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PIK3CB—breast cancer	3.99e-06	3.95e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR downstream signaling—AKT1—breast cancer	3.98e-06	3.94e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CASP3—breast cancer	3.95e-06	3.91e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—IL2—breast cancer	3.94e-06	3.9e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—SRC—breast cancer	3.93e-06	3.89e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—IL6—breast cancer	3.92e-06	3.88e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—MAPK3—breast cancer	3.88e-06	3.84e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CCND1—breast cancer	3.84e-06	3.8e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—JUN—breast cancer	3.83e-06	3.8e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CXCL8—breast cancer	3.83e-06	3.79e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—VEGFA—breast cancer	3.83e-06	3.79e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—MAPK3—breast cancer	3.83e-06	3.79e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—HRAS—breast cancer	3.81e-06	3.77e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CTNNB1—breast cancer	3.8e-06	3.77e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—STAT3—breast cancer	3.79e-06	3.76e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—MYC—breast cancer	3.77e-06	3.74e-05	CbGpPWpGaD
Dipivefrin—ACHE—Metabolism—AKT1—breast cancer	3.77e-06	3.73e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—TGFB1—breast cancer	3.76e-06	3.73e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	3.74e-06	3.7e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—MMP9—breast cancer	3.73e-06	3.69e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—MYC—breast cancer	3.72e-06	3.69e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CDKN1A—breast cancer	3.72e-06	3.68e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—TGFB1—breast cancer	3.72e-06	3.68e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PTEN—breast cancer	3.71e-06	3.67e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	3.7e-06	3.66e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—EGFR—breast cancer	3.69e-06	3.65e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CASP3—breast cancer	3.67e-06	3.63e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—IL2—breast cancer	3.66e-06	3.63e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—EGFR—breast cancer	3.64e-06	3.61e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—IL6—breast cancer	3.64e-06	3.61e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—MAPK8—breast cancer	3.63e-06	3.59e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—MAPK3—breast cancer	3.62e-06	3.59e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—AKT1—breast cancer	3.62e-06	3.58e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—PIK3CA—breast cancer	3.58e-06	3.54e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CCND1—breast cancer	3.57e-06	3.53e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—JUN—breast cancer	3.56e-06	3.53e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	3.53e-06	3.5e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—MYC—breast cancer	3.52e-06	3.49e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—TGFB1—breast cancer	3.52e-06	3.48e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—KRAS—breast cancer	3.49e-06	3.45e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—MMP9—breast cancer	3.47e-06	3.43e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	3.45e-06	3.42e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—EGFR—breast cancer	3.45e-06	3.41e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PTEN—breast cancer	3.44e-06	3.41e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—KRAS—breast cancer	3.44e-06	3.41e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—SRC—breast cancer	3.44e-06	3.4e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—MAPK8—breast cancer	3.37e-06	3.34e-05	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—AKT1—breast cancer	3.36e-06	3.33e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—AKT1—breast cancer	3.36e-06	3.33e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—VEGFA—breast cancer	3.35e-06	3.32e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—STAT3—breast cancer	3.32e-06	3.28e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—KRAS—breast cancer	3.26e-06	3.22e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—PIK3CA—breast cancer	3.2e-06	3.17e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—SRC—breast cancer	3.19e-06	3.16e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—MAPK3—breast cancer	3.17e-06	3.14e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—PIK3CA—breast cancer	3.16e-06	3.13e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—VEGFA—breast cancer	3.11e-06	3.08e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—TP53—breast cancer	3.1e-06	3.07e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—MYC—breast cancer	3.08e-06	3.05e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—STAT3—breast cancer	3.08e-06	3.05e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—TGFB1—breast cancer	3.07e-06	3.04e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—TP53—breast cancer	3.06e-06	3.03e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—EGFR—breast cancer	3.01e-06	2.98e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—PIK3CA—breast cancer	2.99e-06	2.96e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—HRAS—breast cancer	2.96e-06	2.93e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—MAPK3—breast cancer	2.94e-06	2.91e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—HRAS—breast cancer	2.93e-06	2.9e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—AKT1—breast cancer	2.92e-06	2.89e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PIK3CA—breast cancer	2.91e-06	2.88e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—TP53—breast cancer	2.89e-06	2.87e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—MYC—breast cancer	2.86e-06	2.83e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—TGFB1—breast cancer	2.86e-06	2.83e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—KRAS—breast cancer	2.85e-06	2.82e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—IL6—breast cancer	2.84e-06	2.81e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—IL6—breast cancer	2.8e-06	2.77e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—EGFR—breast cancer	2.8e-06	2.77e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—HRAS—breast cancer	2.77e-06	2.74e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—IL6—breast cancer	2.65e-06	2.62e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—KRAS—breast cancer	2.65e-06	2.62e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—AKT1—breast cancer	2.62e-06	2.59e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	2.62e-06	2.59e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—AKT1—breast cancer	2.58e-06	2.56e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—TP53—breast cancer	2.53e-06	2.51e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—AKT1—breast cancer	2.44e-06	2.42e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	2.43e-06	2.41e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—HRAS—breast cancer	2.42e-06	2.4e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—AKT1—breast cancer	2.37e-06	2.35e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—TP53—breast cancer	2.35e-06	2.33e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—IL6—breast cancer	2.32e-06	2.29e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—HRAS—breast cancer	2.25e-06	2.23e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—IL6—breast cancer	2.15e-06	2.13e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—AKT1—breast cancer	2.14e-06	2.12e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—AKT1—breast cancer	1.99e-06	1.97e-05	CbGpPWpGaD
